0032 GMT - Breathing mask maker Fisher & Paykel Healthcare adds Morgan Stanley to its bulls despite tariff headwinds in FY 2026. Fisher & Paykel Healthcare's share price eased after its annual result, which analyst David L. Bailey attributes to weaker-than-expected FY 2026 revenue and net profit guidance. Still, MS thinks growth in new apps revenue will support group-wide revenue over the medium term, with margin improvement underpinning attractive EPS growth. "While valuations are elevated, Fisher & Paykel Healthcare compares favorably relative to the sector on a number of key financial metrics," says MS, as it upgrades to the stock overweight from equal-weight. It expects Fisher & Paykel Healthcare will achieve its gross margin target of 65% in FY 2028, and its Ebit margin goal of 30% in FY 2029. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 01, 2025 20:32 ET (00:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.